References - The Lung Health & Medicine Revolution

European Lung White Book

  1. Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B. The European Lung White Book. Sheffield, European Respiratory Society, 2013.

Burden of respiratory diseases

  1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.
  2. European Centre for Disease Prevention and Control/World Health Organization Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm, European Centre for Disease PreventionControl, 2012.
  3. Eurostat. Hospital discharges by diagnosis, last updated March 2012.
  4. International Agency for Research on Cancer. European Cancer Observatory. Last accessed June 2012.
  5. Lai CKW, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood. Thorax 2009; 64: 476–483.
  6. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863–868.
  7. Organisation for Economic Co-operation and Development. Health Data 2012 - Frequently Requested Data, last accessed January 2012.
  8. The Global Burden of Disease Study 2010. Lancet 2012; 380: 2053–2260. (Interactive versions of this large dataset are available online)
  9. Vanfleteren LE, Franssen FM, Wesseling G, et al. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respir Med 2012; 106: 871–874.
  10. World Health Organization. World Health Statistics 2011, last accessed April 2012.
  11. World Health Organization. World Detailed Mortality Datafiles, last updated November 2011.
  12. World Health Organization. WHO Europe Detailed Mortality Datafiles, last accessed April 2012.
  13. World Health Organization. European Hospital Morbidity Database. Copenhagen, WHO Regional Office for Europe. Last updated October 2011.
  14. World Health Organization. World Health Survey, last accessed January 2012.

State and Future of Respiratory Research

  1. Ayres J, Forsberg B, Annesi-Maesano I, et al. Climate change and respiratory disease: European Respiratory Society position statement. Eur Respir J 2009; 34: 295–302.
  2. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357:1946–1955.
  3. Beldorbos M, Levy O, Bont L. Neonatal innate immunity in allergy development. Curr Opin Pediatr 2009; 21: 762–769.
  4. Bentley AR, Kritchevsky SB, Harris TB, et al. Dietary antioxydants and forced expiratory volume in 1 s decline: the Health, Aging and Body Composition study. Eur Respir J 2012; 39: 979–984.
  5. Bisgaard H, Hermansen MN, Bonnelykke K, et al. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. BMJ 2010; 341: c49–c78.
  6. Camus P, Foucher P, Bonniaud P, et al. Drug-induced infiltrative lung disease. Eur Respir J 2001; 18: Suppl. 32, 93s–100s.
  7. Decramer M, Sibille Y, Bush A, et al. The European Union Conference on chronic respiratory disease: purpose and conclusion. Eur Respir J 2011; 37: 738–742.
  8. Directorate-General for Research and Innovation, European Commission. Health Research in FP7. Catalogue number KI-81-08-344-EN-C. Luxembourg, Office for Official Publications of the European Union, 2008.
  9. Grasemann H, Ratjen F. Emerging therapies for cystic fibrosis lung disease. Expert Opin Emerg Drugs 2010; 15: 653–659.
  10. ten Hacken NH. Physical inactivity and obesity. Relation to asthma and chronic obstructive pulmonary disease? Proc Am Thorac Soc 2009; 6: 663–667.
  11. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173–180.
  12. Kabesch M, Michel S, Tost J. Epigenetic mechanisms and the relationship to childhood asthma. Eur Respir J 2010; 36: 950–961.
  13. Lam C, Barry A, Borlaug MD. et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009; 119: 2663–2670.
  14. de Leeuw F, Horalek J. Assessment of the health impacts of exposure to PM2.5 at a European level. Bilthoven, European Topic Centre on Air and Climate Change, 2009.
  15. Mason CM, Nelson S. Pulmonary host defenses and factors predisposing to lung infection. Clin Chest Med 2005; 26: 11–17.
  16. Meyer KC. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. Semin Respir Crit Care Med 2010; 31: 561–574.
  17. Murray JF. The year of the lung. Int J Tuberc Lung Dis 2010; 14: 1–4.
  18. Nicod LP, Kamel N, Ward B, et al. ERS is founding member of a new Alliance for Biomedical Research in Europe. Eur Respir J 2011; 38: 237–238.
  19. Perera F, Herbstman J. Prenatal environmental exposures, epigenetics, and disease. Reprod Toxicol 2011; 31: 363–373.
  20. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379: 1902–1913.
  21. Richard J, Castriotta MD, Basil A, et al. Workshop on idiopathic pulmonary fibrosis in older adults. Chest 2010; 138: 693–703.
  22. Samolinski B, Fronczak A, Wlodarczyk A, et al. Council of the European Union conclusions on chronic respiratory diseases in children. Lancet 2012; 379: e45–e46.
  23. Sigsgaard T, Nowak D, Annesi-Maesano I, et al. ERS position paper: work-related respiratory diseases in the EU. Eur Respir J 2010; 35: 234–238.
  24. Turner M, Krewski D, Chen Y, et al. Radon and COPD mortality in the American Cancer Society Cohort. Eur Respir J 2012; 39: 1113–1119.
  25. Viasus D, Pano-Pardo J, Cordero E, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011; 62: 193–199.
  26. WHO guidelines for indoor air quality: selected pollutants. Bonn, World Health Organization European Centre for Environment and Health, 2010.
  27. Wylie KM, Weinstock GM, Storch GA. Emerging view of the human virome. Transl Res 2012; 160: 283–290.
  28. Xu X, Rock JR, Lu Y. et al. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc Natl Acad Sci USA 2012; 109: 4910–4915.

Personalized medicine

  1. Bliss M. William Osler: A life in Medicine. Oxford University Press, NY, NY, USA. 1999. pp1-581.
  2. Bousquet J, Anto JM, Sterk PJ, Adcock IM, Chung KF, Roca J, Agusti A, Brightling C, Cambon-Thomsen A, Cesario A, Abdelhak S, Antonarakis SE, Avignon A, Ballabio A, Baraldi E, Baranov A, Bieber T, Bockaert J, Brahmachari S, Brambilla C, Bringer J, Dauzat M, Ernberg I, Fabbri L, Froguel P, Galas D, Gojobori T, Hunter P, Jorgensen C, Kauffmann F, Kourilsky P, Kowalski ML, Lancet D, Pen CL, Mallet J, Mayosi B, Mercier J, Metspalu A, Nadeau JH, Ninot G, Noble D, Oztürk M, Palkonen S, Préfaut C, Rabe K, Renard E, Roberts RG, Samolinski B, Schünemann HJ, Simon HU, Soares MB, Superti-Furga G, Tegner J, Verjovski-Almeida S, Wellstead P, Wolkenhauer O, Wouters E, Balling R, Brookes AJ, Charron D, Pison C, Chen Z, Hood L, Auffray C. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med. 2011 Jul 6;3(7):43. doi: 10.1186/gm259
  3. Holgate ST. A look at the pathogenesis of asthma: the need for a change in direction. Discov Med. 2010 May;9(48):439-47.
  4. Cutting the cost of drug development? Rawlins MD. Nat Rev Drug Discov. 2004: 3; 360-4.
  5. Holgate ST. Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol. 2012; 33: 238-46.
  6. Holgate ST. Stratified approaches to the treatment of asthma. Br J Clin Pharmacol. 2012 Nov 16. doi: 10.1111/bcp.12036. [Epub ahead of print].
  7. Harvey A, Brand A, Holgate ST, Kristiansen LV, Lehrach H, Palotie A, Prainsack B. The future of technologies for personalised medicine. N Biotechnol. 2012 Sep 15;29(6):625-33.
  8. Holgate, ST, Palotie, A, Prainsack,ESF Forward Look: Personalised Medicine for the European Citizen - Towards more precise medicine for the diagnosis, treatment and prevention of disease (iPM). European Science Foundation 1 quai Lezay-Marnésia,  BP 90015 67080 Strasbourg cedex,  France..
  9. Kaminsky DA, Irvin CG, Sterk PJ. Complex systems in pulmonary medicine: a systems biology approach to lung disease. J Appl Physiol. 2011 Jun;110(6):1716-22.
  10. Raparia K, Villa C, DeCamp MM, Patel JD, Mehta MP. Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. Arch Pathol Lab Med. 2013; 137: 481-91.
  11. Sterk PJ, Ricciardolo FL. Clinical-biological phenotyping beyond inflammation in asthma delivers. Am J Respir Crit Care Med. 2013; 187: 117-8.
  12. Wheelock CE, Goss VM, Balgoma D, Nicholas B, Brandsma J, Skipp PJ, Snowden S, D'Amico A, Horvath I, Chaiboonchoe A, Ahmed H, Ballereau S, Rossios C, Chung KF, Montuschi P, Fowler SJ, Adcock IM, Postle AD, Dahlén SE, Rowe A, Sterk PJ, Auffray C, Djukanovic R; the U-BIOPRED Study Group. Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J. 2013 Feb 8. [Epub ahead of print].

European Commission Initiative

  1. European Research Area
  2. Horizon 2020

Public – Private Partnerships

  1. A Christini. Why universities should step up in venture investing. Nature Biotechnology 30 (10), 933 : 936, 2012
  2. Editorial. Lessons from Lipitor and the broken blockbuster model. Lancet. 378 : 1976, 2011
  3. European Federation of Pharmaceutical Industries and Association
  4. EvaluatePharma - World Preview 2018 Embracing the Patent Cliff. EvaluatePharma Ltd. 2012
  5. M Goldman. Public private partnerships need honest brokering. Nature Medicine 18(3), 341, 2012
  6. Innovative Medicine Initiative
  7. DR Janero. Producing university, industry and government relationships in preclinical drug discovery and development : considerations toward a synergistic lingua franca. Expert Opin Drug Discov , 2012
  8. CP Milne, A Malins. Academic – Industry Partnerships for Biopharmaceutical Research & Development : Advancing Medical Sciences in the US. Tufts Center for the Study of Drug Development, 2012
  9. U-BIOPRED
  10. P Vallance, P Williams, C. Dollery. The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clinical Pharmacology & Therapeutics 87(5), 525:7, 2010

Role of patients and patients organisations

  1. Appraisal of Guidelines Research & Evaluation
  2. Berger B, et al. Training of patient and consumer representatives in the basic competencies of evidence-based medicine: a feasibility study. BMC Medical Education 2010; 10: 16.
  3. Caron-Flinterman JF, et al. Patients' priorities concerning health research: the case of asthma and COPD research in the Netherlands. Health Expect 2005, 8: 253-263.
  4. Chalmers I. What do I want from health research and researchers when I am a patient. BMJ 1995; 310: 1315-1318.
  5. Coulter A, Ellins J. Effectiveness of strategies for informing, educating, and involving patients. BMJ 2007; 335; 24-27.
  6. Coulter A. Patient engagement: why is it important? In: Andersson E, Tritter J and Wilson R (Eds). Healthy Democracy: The future of involvement in health and social care. London, NHS, The National Centre for Involvement, 2006.
  7. Department of Health, Best Research for Best Health: A New National Health Research Strategy. 2006, Department of Health London.
  8. Fletcher M, Wedzicha W. Making ERS guidelines relevant and accessible – involving patients and the public. Breathe 2011; 8: 9-11.
  9. Gagliardi AR, et al. Barriers to patient involvement in health service planning and evaluation: an exploratory study. Patient Educ Couns 2008; 70:234-41.
  10. Nielsen ES, et al. Methods of consumer involvement in developing healthcare policy and research, clinical practice guideline and patient information material. Issue 3. Cochrane Database Syst Rev 2006: CD004563.

The ERS Vision film series is made possible through a foundation sponsorship by astrazeneca